
Please try another search
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Antoine Yver | 67 | - | Chairman of Scientific Advisory Board |
Ling Su | 60 | - | Member of Scientific Advisory Board |
Dong Xie | 45 | 2025 | Independent Non-Executive Director |
Zhiyang Cai | 43 | 2024 | Non-Executive Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
Fengyong Gao | 55 | 2025 | Independent Non-Executive Director |
Tao Yu | 39 | 2021 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review